Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

Elizabeth T H Fontham, Andrew M D Wolf, Timothy R Church, Ruth Etzioni, Christopher R Flowers, Abbe Herzig, Carmen E Guerra, Kevin C Oeffinger, Ya-Chen Tina Shih, Louise C Walter, Jane J Kim, Kimberly S Andrews, Carol E DeSantis, Stacey A Fedewa, Deana Manassaram-Baptiste, Debbie Saslow, Richard C Wender, Robert A Smith, Elizabeth T H Fontham, Andrew M D Wolf, Timothy R Church, Ruth Etzioni, Christopher R Flowers, Abbe Herzig, Carmen E Guerra, Kevin C Oeffinger, Ya-Chen Tina Shih, Louise C Walter, Jane J Kim, Kimberly S Andrews, Carol E DeSantis, Stacey A Fedewa, Deana Manassaram-Baptiste, Debbie Saslow, Richard C Wender, Robert A Smith

Abstract

The American Cancer Society (ACS) recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 years through age 65 years (preferred); if primary HPV testing is not available, then individuals aged 25 to 65 years should be screened with cotesting (HPV testing in combination with cytology) every 5 years or cytology alone every 3 years (acceptable) (strong recommendation). The ACS recommends that individuals aged >65 years who have no history of cervical intraepithelial neoplasia grade 2 or more severe disease within the past 25 years, and who have documented adequate negative prior screening in the prior 10 years, discontinue all cervical cancer screening (qualified recommendation). These new screening recommendations differ in 4 important respects compared with the 2012 recommendations: 1) The preferred screening strategy is primary HPV testing every 5 years, with cotesting and cytology alone acceptable where access to US Food and Drug Administration-approved primary HPV testing is not yet available; 2) the recommended age to start screening is 25 years rather than 21 years; 3) primary HPV testing, as well as cotesting or cytology alone when primary testing is not available, is recommended starting at age 25 years rather than age 30 years; and 4) the guideline is transitional, ie, options for screening with cotesting or cytology alone are provided but should be phased out once full access to primary HPV testing for cervical cancer screening is available without barriers. Evidence related to other relevant issues was reviewed, and no changes were made to recommendations for screening intervals, age or criteria for screening cessation, screening based on vaccination status, or screening after hysterectomy. Follow-up for individuals who screen positive for HPV and/or cytology should be in accordance with the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.

Keywords: cervical neoplasms; cervix neoplasms; guideline; mass screening; prevention and control.

© 2020 American Cancer Society.

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7-30.
    1. Islami F, Fedewa SA, Jemal A. Trends in cervical cancer incidence rates by age, race/ethnicity, histological subtype, and stage at diagnosis in the United States. Prev Med. 2019;123:316-323.
    1. Castanon A, Landy R, Sasieni PD. Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? Int J Cancer. 2016;139:1040-1045.
    1. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320:687-705.
    1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62:147-172.
    1. Schiffman M, Doorbar J, Wentzensen N, et al. Carcinogenic human papillomavirus infection. Nat Rev Dis Primers. 2016;2:16086.
    1. McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence of HPV in adults aged 18-69: United States, 2011-2014. NCHS Data Brief. 2017;280:1-8.
    1. Loopik DL, Doucette S, Bekkers RL, Bentley JR. Regression and progression predictors of CIN2 in women younger than 25 years. J Low Genit Tract Dis. 2016;20:213-217.
    1. de Sanjose S, Brotons M, Pavon MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2-13.
    1. Bekos C, Schwameis R, Heinze G, et al. Influence of age on histologic outcome of cervical intraepithelial neoplasia during observational management: results from large cohort, systematic review, meta-analysis. Sci Rep. 2018;8:6383.
    1. Demarco M, Hyun N, Carter-Pokras O, et al. A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programs. EClinicalMedicine. 2020;22:100293.
    1. Lenhoff A. The five FDA-approved HPV assays. Medical Laboratory Observer. July 1, 2012.
    1. Nelson R. FDA OKs HPV DNA test for primary cervical cancer screening. Medscape Medical News. April 24, 2014.
    1. US Food and Drug Administration (FDA). FDA Executive Summary: New Approaches in the Evaluation for High-Risk Human Papillomavirus Nucleic Acid Detection Devices. Prepared for the March 8, 2019 meeting of the Microbiology Devices Panel of the Medical Devices Advisory Committee. FDA; 2019. Accessed March 23, 2020.
    1. Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320:674-686.
    1. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136:178-182.
    1. Salazar KL, Duhon DJ, Olsen R, Thrall M. A review of the FDA-approved molecular testing platforms for human papillomavirus. J Am Soc Cytopathol. 2019;8:284-292.
    1. Castle PE, Xie X, Xue X, et al. Impact of human papillomavirus vaccination on the clinical meaning of cervical screening results. Prev Med. 2019;118:44-50.
    1. Castle PE, Kinney WK, Xue X, et al. Role of screening history in clinical meaning and optimal management of positive cervical screening results. J Natl Cancer Inst. 2019;111:820-827.
    1. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
    1. Perkins RB, Guido RL, Castle PE, et al; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J Low Genit Tract Dis. 2020;24:29.
    1. Zhao C, Crothers BA, Ghofrani M, et al. Human papillomavirus genotyping testing practice in 2014: results of a College of American Pathologists national survey. Arch Pathol Lab Med. 2016;140:1364-1370.
    1. Zhao C, Moriarty AT, Ghofrani M, et al. Human papillomavirus testing and reporting rates in 2012: results of a College of American Pathologists national survey. Arch Pathol Lab Med. 2015;139:757-761.
    1. Watson M, Benard V, Flagg EW. Assessment of trends in cervical cancer screening rates using healthcare claims data: United States, 2003-2014. Prev Med Rep. 2018;9:124-130.
    1. Watson M, Benard V, King J, Crawford A, Saraiya M. National assessment of HPV and Pap tests: changes in cervical cancer screening, National Health Interview Survey. Prev Med. 2017;100:243-247.
    1. Kim JJ, Burger EA, Sy S, Campos NG. Optimal cervical cancer screening in women vaccinated against human papillomavirus. J Natl Cancer Inst. 2016;109:djw216.
    1. Naber SK, Matthijsse SM, Rozemeijer K, Penning C, de Kok IM, van Ballegooijen M. Cervical cancer screening in partly HPV vaccinated cohorts-a cost-effectiveness analysis. PLoS One. 2016;11:e0145548.
    1. Pedersen K, Burger EA, Nygard M, Kristiansen IS, Kim JJ. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: the value of stratifying guidelines. Eur J Cancer. 2018;91:68-75.
    1. Simms KT, Smith MA, Lew JB, Kitchener HC, Castle PE, Canfell K. Will cervical screening remain cost-effective in women offered the next generation nonavalent HPV vaccine? Results for four developed countries. Int J Cancer. 2016;139:2771-2780.
    1. Walker TY, Elam-Evans LD, Singleton JA, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2016. MMWR Morb Mortal Wkly Rep. 2017;66:874-882.
    1. Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2017. MMWR Morb Mortal Wkly Rep. 2018;67:909-917.
    1. Walker TY, Elam-Evans LD, Yankey D, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years-United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68:718-723.
    1. Boersma P, Black LI. Human Papillomavirus Vaccination Among Adults Aged 18-26, 2013-2018. NCHS Data Brief no. 354. National Center for Health Statistics; 2020.
    1. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 2017;14:e1002388.
    1. Palmer T, Wallace L, Pollock KG, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. BMJ. 2019;365:l1161.
    1. Racey CS, Albert A, Donken R, et al. Cervical intraepithelial neoplasia rates in British Columbia women: a population-level data linkage evaluation of the school-based HPV immunization program. J Infect Dis. 2020;221:81-90.
    1. McClung NM, Gargano JW, Bennett NM, et al. Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008-2014. Cancer Epidemiol Biomarkers Prev. 2019;28:602-609.
    1. McClung NM, Lewis RM, Gargano JW, Querec T, Unger ER, Markowitz LE. Declines in vaccine-type human papillomavirus prevalence in females across racial/ethnic groups: data from a national survey. J Adolesc Health. 2019;65:715-722.
    1. Wright TC Jr, Parvu V, Stoler MH, et al. HPV infections and cytologic abnormalities in vaccinated women 21-34years of age: results from the baseline phase of the Onclarity trial. Gynecol Oncol. 2019;153:259-265.
    1. Brawley O, Byers T, Chen A, et al. New American Cancer Society process for creating trustworthy cancer screening guidelines. JAMA. 2011;306:2495-2499.
    1. Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA. 2015;314:1599-1614.
    1. Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018;68:250-281.
    1. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Soulsby MA. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis, No. 2058. Agency for Healthcare Research and Quality (US); 2018. Accessed May 1, 2020.
    1. Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA. 2018;320:706-714.
    1. Kim JJ, Burger EA, Regan C, Sy S. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality (US); 2018. Accessed May 1, 2020.
    1. North American Association of Central Cancer Registries (NAACCR). NAACCR Incidence Data-Cancer in North America (CiNA) Analytic File, 1995-2016, Public Use (which includes data from the Centers for Disease Control and Prevention's National Program of Cancer Registries [NPCR], the Canadian Counsel of Cancer Registries Provincial and Territorial Registries, and the National Cancer Institute's SEER Registries), certified by the NAACCR as meeting high-quality incidence data standards for the specified time periods. NAACCR; 2019.
    1. Surveillance, Epidemiology, and End Results (SEER) Program (). SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1990-2017) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, released December 2019. Underlying mortality data provided by National Center for Health Statistics.
    1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence-Based Mortality-SEER 18 Registries (Excluding Louisiana) Research Data, November 2018 Submission (2000-2016) <Katrina/Rita Population Adjustment>-Linked To County Attributes-Total U.S., 1969-2017 Counties. Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute; 2019.
    1. Alonso-Coello P, Schunemann HJ, Moberg J, et al. GRADE evidence to decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 2016;353:i2016.
    1. Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ. 2016;354:i3633.
    1. Bloomfield HE, Olson A, Greer N, et al. Screening pelvic examinations in asymptomatic, average-risk adult women: an evidence report for a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161:46-53.
    1. Habbema D, Weinmann S, Arbyn M, et al. Harms of cervical cancer screening in the United States and the Netherlands. Int J Cancer. 2017;140:1215-1222.
    1. Perkins RB, Anderson BL, Gorin SS, Schulkin JA. Challenges in cervical cancer prevention: a survey of U.S. obstetrician-gynecologists. Am J Prev Med. 2013;45:175-181.
    1. Cooper CP, Saraiya M. Cervical cancer screening intervals preferred by U.S. women. Am J Prev Med. 2018;55:389-394.
    1. Pratte MA, Griffin A, Ogazi C, et al. Racial/ethnic disparities in cervical cancer screening services among contractors of the Connecticut Breast and Cervical Cancer Early Detection Program. Health Equity. 2018;2:30-36.
    1. White MC, Shoemaker ML, Benard VB. Cervical cancer screening and incidence by age: unmet needs near and after the stopping age for screening. Am J Prev Med. 2017;53:392-395.
    1. Thiel de Bocanegra H, Navarro SK, Nonzee NJ, et al. Trends in cervical cancer screening in California's family planning program. J Low Genit Tract Dis. 2018;22:171-177.
    1. Yu L, Sabatino SA, White MC. Rural-urban and racial/ethnic disparities in invasive cervical cancer incidence in the United States, 2010-2014. Prev Chronic Dis. 2019;16:E70.
    1. Benard VB, Thomas CC, King J, et al. Vital signs: cervical cancer incidence, mortality, and screening-United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014;63:1004-1009.
    1. Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123:1044-1050.
    1. Hall IJ, Tangka FKL, Sabatino SA, Thompson TD, Graubard BI, Breen N. Patterns and trends in cancer screening in the United States. Prev Chronic Dis. 2018;15:E97.
    1. Fedewa SA, Cokkinides V, Virgo KS, Bandi P, Saslow D, Ward EM. Association of insurance status and age with cervical cancer stage at diagnosis: National Cancer Database, 2000-2007. Am J Public Health. 2012;102:1782-1790.
    1. Yoo W, Kim S, Huh WK, et al. Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One. 2017;12:e0172548.
    1. Castle PE, Kinney WK, Cheung LC, et al. Why does cervical cancer occur in a state-of-the-art screening program? Gynecol Oncol. 2017;146:546-553.
    1. Dinkelspiel H, Fetterman B, Poitras N, et al. Screening history preceding a diagnosis of cervical cancer in women age 65 and older. Gynecol Oncol. 2012;126:203-206.
    1. Eddy D. Cervical cancer screening. CA Cancer J Clin. 1980;30:215-223.
    1. Fink DJ. Change in American Cancer Society checkup guidelines for detection of cervical cancer. CA Cancer J Clin. 1988;38:127-128.
    1. Moscicki AB, Cox JT. Practice Improvement in Cervical Screening and Management (PICSM): symposium on management of cervical abnormalities in adolescents and young women. J Low Genit Tract Dis. 2010;14:73-80.
    1. Fontaine PL, Saslow D, King VJ. ACS/ASCCP/ASCP guidelines for the early detection of cervical cancer. Am Fam Physician. 2012;86:501, 506-507.
    1. Moyer VA, U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880-891, W312.
    1. US Census Bureau. Estimates of the Residential Population by Single Year of Age and Sex for the United States: April 1, 2010 to July 1, 2017. Accessed November 9, 2018.
    1. Vesco KK, Whitlock EP, Eder M, Burda BU, Senger CA, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:698-705, w216.
    1. Argyri E, Papaspyridakos S, Tsimplaki E, et al. A cross sectional study of HPV type prevalence according to age and cytology. BMC Infect Dis. 2013;13:53.
    1. Stoler MH, Wright TC, Parvu V, et al. The Onclarity Human Papillomavirus Trial: design, methods, and baseline results. Gynecol Oncol. 2018;149:498-505.
    1. Ronco G, Dillner J, Elfstrom KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524-532.
    1. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11:249-257.
    1. Moscicki AB, Shiboski S, Hills NK, et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet. 2004;364:1678-1683.
    1. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423-428.
    1. Katki HA, Schiffman M, Castle PE, et al. Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years. J Low Genit Tract Dis. 2013;17(5 suppl 1):S64-S68.
    1. Wentzensen N, Nason M, Schiffman M, Dodd L, Hunt WC, Wheeler CM. No evidence for synergy between human papillomavirus genotypes for the risk of high-grade squamous intraepithelial lesions in a large population-based study. J Infect Dis. 2014;209:855-864.
    1. Castanon A, Leung VMW, Landy R, Lim AWW, Sasieni P. Characteristics and screening history of women diagnosed with cervical cancer aged 20-29 years. Br J Cancer. 2013;109:35-41.
    1. Lonnberg S, Anttila A, Luostarinen T, Nieminen P. Age-specific effectiveness of the Finnish cervical cancer screening programme. Cancer Epidemiol Biomarkers Prev. 2012;21:1354-1361.
    1. Sasieni P, Adams J, Cuzick J. Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer. 2003;89:88-93.
    1. Sasieni P, Castanon A, Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009;339:b2968.
    1. Zappa M, Visioli CB, Ciatto S, Iossa A, Paci E, Sasieni P. Lower protection of cytological screening for adenocarcinomas and shorter protection for younger women: the results of a case-control study in Florence. Br J Cancer. 2004;90:1784-1786.
    1. Landy R, Birke H, Castanon A, Sasieni P. Benefits and harms of cervical screening from age 20 years compared with screening from age 25 years. Br J Cancer. 2014;110:1841-1846.
    1. Maura G, Chaignot C, Weill A, Alla F, Heard I. Cervical cancer screening and subsequent procedures in women under the age of 25 years between 2007 and 2013 in France: a nationwide French healthcare database study. Eur J Cancer Prev. 2018;27:479-485.
    1. Tainio K, Athanasiou A, Tikkinen KAO, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018;360:k499.
    1. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after conservative treatment for cervical intraepithelial neoplasia. Cochrane Database Syst Rev. 2015;9:CD008478.
    1. McClung NM, Gargano JW, Park IU, et al. Estimated number of cases of high-grade cervical lesions diagnosed among women -United States, 2008 and 2016. MMWR Morb Mortal Wkly Rep. 2019;68:337-343.
    1. Gargano JW, Park IU, Griffin MR, et al. Trends in high-grade cervical lesions and cervical cancer screening in 5 states, 2008-2015. Clin Infect Dis. 2019;68:1282-1291.
    1. Oliver SE, Unger ER, Lewis R, et al. Prevalence of human papillomavirus among females after vaccine introduction-National Health and Nutrition Examination Survey, United States, 2003-2014. J Infect Dis. 2017;216:594-603.
    1. Wright TC Jr, Stoler MH, Parvu V, et al. Detection of cervical neoplasia by human papillomavirus testing in an atypical squamous cells-undetermined significance population: results of the Becton Dickinson Onclarity trial. Am J Clin Pathol. 2019;151:53-62.
    1. Wright TC Jr, Stoler MH, Parvu V, Yanson K, Cooper C, Andrews J. Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21years of age, with ASC-US or LSIL cytology. Gynecol Oncol. 2019;154:360-367.
    1. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review and meta-analysis. BMC Infect Dis. 2011;11:13.
    1. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(suppl 5):F123-F138.
    1. Leinonen MK, Nieminen P, Lonnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789.
    1. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320:43-52.
    1. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111.
    1. Castle PE, Kinney WK, Xue X, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study. Ann Intern Med. 2018;168:20-29.
    1. Zhao C, Weng B, Li Z, Yang H, Austin RM. Follow-up outcomes of a large cohort of low-risk women with negative imaged liquid-based cytology and negative HPV test results. Am J Clin Pathol. 2013;139:32-38.
    1. Wright TC, Stoler MH, Behrens CM, Sharma A, Zhang G, Wright TL. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015;136:189-197.
    1. Practice Bulletin No. 168 summary: cervical cancer screening and prevention. Obstet Gynecol. 2016;128:923-925.
    1. Andrae B, Kemetli L, Sparen P, et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst. 2008;100:622-629.
    1. Anttila A, Kotaniemi-Talonen L, Leinonen M, et al. Rate of cervical cancer, severe intraepithelial neoplasia, and adenocarcinoma in situ in primary HPV DNA screening with cytology triage: randomised study within organised screening programme. BMJ. 2010;340:c1804.
    1. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol. 2011;12:663-672.
    1. Berg AO, Atkins D, Tierney W. Clinical practice guidelines in practice and education. J Gen Intern Med. 1997;12(suppl 2):S25-S33.
    1. Castanon A, Landy R, Cuzick J, Sasieni P. Cervical screening at age 50-64 years and the risk of cervical cancer at age 65 years and older: population-based case control study. PLoS Med. 2014;11:e1001585.
    1. Wang J, Andrae B, Sundstrom K, et al. Effectiveness of cervical screening after age 60 years according to screening history: nationwide cohort study in Sweden. PLoS Med. 2017;14:e1002414.
    1. Kamineni A, Weinmann S, Shy KK, Glass AG, Weiss NS. Efficacy of screening in preventing cervical cancer among older women. Cancer Causes Control. 2013;24:1653-1660.
    1. Rosenblatt KA, Osterbur EF, Douglas JA. Case-control study of cervical cancer and gynecologic screening: a SEER-Medicare analysis. Gynecol Oncol. 2016;142:395-400.
    1. Landy R, Schiffman M, Sasieni PD, et al. Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. Int J Cancer. 2020;146:617-626.
    1. Malagón T, Kulasingam S, Mayrand MH, et al. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study. Lancet Oncol. 2018;19:1569-1578.
    1. Gravitt PE, Landy R, Schiffman M. How confident can we be in the current guidelines for exiting cervical screening? Prev Med. 2018;114:188-192.
    1. Rositch AF, Burke AE, Viscidi RP, Silver MI, Chang K, Gravitt PE. Contributions of recent and past sexual partnerships on incident human papillomavirus detection: acquisition and reactivation in older women. Cancer Res. 2012;72:6183-6190.
    1. Burger EA, Kim JJ, Sy S, Castle PE. Age of acquiring causal human papillomavirus (HPV) infections: leveraging simulation models to explore the natural history of HPV-induced cervical cancer. Clin Infect Dis. 2017;65:893-899.
    1. Elit L. Role of cervical screening in older women. Maturitas. 2014;79:413-420.
    1. Isidean SD, Franco EL. Counterpoint: cervical cancer screening guidelines-approaching the golden age. Am J Epidemiol. 2013;178:1023-1026; discussion 1027.
    1. Hermansson RS, Olovsson M, Hoxell E, Lindstrom AK. HPV prevalence and HPV-related dysplasia in elderly women. PLoS One. 2018;13:e0189300.
    1. Rustagi AS, Kamineni A, Weinmann S, Reed SD, Newcomb P, Weiss NS. Cervical screening and cervical cancer death among older women: a population-based, case-control study. Am J Epidemiol. 2014;179:1107-1114.
    1. Lew JB, Simms KT, Smith MA, et al. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program. Lancet Public Health. 2017;2:e96-e107.
    1. Teoh D, Musa F, Salani R, Huh W, Jimenez E. Diagnosis and management of adenocarcinoma in situ: a Society of Gynecologic Oncology evidence-based review and recommendations. Obstet Gynecol. 2020;135:869-878.
    1. Liu G, Sharma M, Tan N, Barnabas RV. HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer. AIDS. 2018;32:795-808.
    1. Masur H, Brooks JT, Benson CA, Holmes KK, Pau AK, Kaplan JE. Prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: updated guidelines from the Centers for Disease Control and Prevention, National Institutes of Health, and HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58:1308-1311.
    1. Kaplan JE, Benson C, Holmes KK, et al. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMRW Recomm Rep. 2009;58(RR-4):1-CE4.
    1. US Department of Health and Human Services. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents With HIV. Accessed April 9, 2020.
    1. Moscicki AB, Flowers L, Huchko MJ, et al. Guidelines for cervical cancer screening in immunosuppressed women without HIV infection. J Low Genit Tract Dis. 2019;23:87-101.
    1. Verloop J, van Leeuwen FE, Helmerhorst TJ, van Boven HH, Rookus MA. Cancer risk in DES daughters. Cancer Causes Control. 2010;21:999-1007.
    1. Rubin MM. Antenatal exposure to DES: lessons learned…future concerns. Obstet Gynecol Surv. 2007;62:548-555.
    1. National Cancer Institute. What should DES-exposed daughters do? Accessed April 25, 2020.
    1. Subramaniam A, Fauci JM, Schneider KE, et al. Invasive cervical cancer and screening: what are the rates of unscreened and underscreened women in the modern era? J Low Genit Tract Dis. 2011;15:110-113.
    1. American Cancer Society. American Cancer Society Cancer Prevention and Early Detection Facts and Figures, Tables & Figures 2020. American Cancer Society; 2020.
    1. Perkins RB. Personal communication. 2020.
    1. Davey DD, Souers RJ, Goodrich K, Mody DR, Tabbara SO, Booth CN. Bethesda 2014 implementation and human papillomavirus primary screening: practices of laboratories participating in the College of American Pathologists PAP Education Program. Arch Pathol Lab Med. 2019;143:1196-1202.
    1. Nayar R, Goulart RA, Davey DD. Primary HPV cervical cancer screening in the United States: are we ready? J Am Soc Cytopathol. 2018;7:50-55.
    1. Meijer CJ, Berkhof J, Castle PE, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009;124:516-520.
    1. Benard VB, Castle PE, Jenison SA, et al. Population-based incidence rates of cervical intraepithelial neoplasia in the human papillomavirus vaccine era. JAMA Oncol. 2017;3:833-837.
    1. Canfell K, Saville M, Caruana M, et al. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia. BMJ Open. 2018;8:e016700.
    1. Misra-Hebert AD. Cervical cancer in African American women: optimizing prevention to reduce disparities. Cleve Clin J Med. 2017;84:795-796.
    1. Hatcher J, Studts CR, Dignan MB, Turner LM, Schoenberg NE. Predictors of cervical cancer screening for rarely or never screened rural Appalachian women. J Health Care Poor Underserved. 2011;22:176-193.
    1. Bains I, Choi YH, Soldan K, Jit M. Clinical impact and cost-effectiveness of primary cytology versus human papillomavirus testing for cervical cancer screening in England. Int J Gynecol Cancer. 2019;29:669-675.
    1. Castanon A, Rebolj M, Sasieni P. Is a delay in the introduction of human papillomavirus-based cervical screening affordable? J Med Screen. 2019;26:44-49.
    1. Madzima TR, Vahabi M, Lofters A. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: focused literature review. Can Fam Physician. 2017;63:597-601.
    1. Yeh PT, Kennedy CE, de Vuyst H, Narasimhan M. Self-sampling for human papillomavirus (HPV) testing: a systematic review and meta-analysis. BMJ Glob Health. 2019;4:e001351.
    1. Tota JE, Bentley J, Blake J, et al. Introduction of molecular HPV testing as the primary technology in cervical cancer screening: acting on evidence to change the current paradigm. Prev Med. 2017;98:5-14.
    1. Bais AG, van Kemenade FJ, Berkhof J, et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer. 2007;120:1505-1510.
    1. Dzuba IG, Diaz EY, Allen B, et al. The acceptability of self-collected samples for HPV testing vs. the Pap test as alternatives in cervical cancer screening. J Womens Health Gend Based Med. 2002;11:265-275.
    1. Crofts V, Flahault E, Tebeu PM, et al. Education efforts may contribute to wider acceptance of human papillomavirus self-sampling. Int J Womens Health. 2015;7:149-154.
    1. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385-1394.
    1. Jeronimo J, Perkins RB, Scalici J, Pierce JY. Should self-sampling be an option for women in the United States? J Low Genit Tract Dis. 2019;23:54-57.
    1. Malone C, Barnabas RV, Buist DSM, Tiro JA, Winer RL. Cost-effectiveness studies of HPV self-sampling: a systematic review. Prev Med. 2020;132:105953.
    1. Winer RL, Tiro JA, Miglioretti DL, et al. Rationale and design of the HOME trial: a pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials. 2018;64:77-87.
    1. American College of Obstetricians and Gynecologists. Cervical Cancer Screening (Update). Accessed April 17, 2020.
    1. Sawaya GF, Kulasingam S, Denberg TD, Qaseem A; Clinical Guidelines Committee of American College of Physicians. Cervical cancer screening in average-risk women: best practice advice from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2015;162:851-859.
    1. Rerucha CM, Caro RJ, Wheeler VL. Cervical cancer screening. Am Fam Physician. 2018;97:441-448.
    1. Community Preventive Services Task Force. What Works-Cancer Screening Evidence-Based Interventions for Your Community. Accessed April 30, 2020.
    1. van der Horst J, Siebers AG, Bulten J, Massuger LF, de Kok IM. Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med. 2017;6:416-423.
    1. Cooper CP, Saraiya M. Primary HPV testing recommendations of US providers, 2015. Prev Med. 2017;105:372-377.
    1. Darwish-Yassine M, Garvin AD, Johnston CM, et al. An assessment of gynecological cytology screening practices among health care providers nationwide. Arch Pathol Lab Med. 2015;139:650-655.
    1. Gerend MA, Shepherd MA, Kaltz EA, Davis WJ, Shepherd JE. Understanding women's hesitancy to undergo less frequent cervical cancer screening. Prev Med. 2017;95:96-102.
    1. Rendle KA, Schiffman M, Cheung LC, et al. Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting. Prev Med. 2018;109:44-50.
    1. MacLaughlin KL, Jacobson RM, Radecki Breitkopf C, et al. Trends over time in Pap and Pap-HPV cotesting for cervical cancer screening. J Womens Health (Larchmt). 2019;28:244-249.
    1. Goding Sauer A, Bandi P, Saslow D, Islami F, Jemal A, Fedewa SA. Geographic and sociodemographic differences in cervical cancer screening modalities. Prev Med. 2020;133:106014.
    1. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening-a study within a randomized trial. Int J Gynecol Cancer. 2008;18:743-748.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi